HempFusion Expands Global Footprint to Europe Through Ireland
January 14 2021 - 7:05AM
Business Wire
HempFusion Wellness Inc. (TSX:CBD.U) (“HempFusion” or the
“Company”), a leading health and wellness CBD company
utilizing the power of whole-food hemp nutrition, is pleased to
announce its entrance into the European market through an exclusive
distribution agreement with a European distributor with an
extensive retail store network. With full acknowledgement of the
Food Safety Authority of Ireland (FSAI), the expansion includes
fully European Union compliant labeling, packaging and distribution
for select HempFusion CBD & Probulin Probiotics products.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210114005361/en/
HempFusion CBD 20mg (Graphic: Business
Wire)
“We are incredibly excited to launch sales into Europe, starting
with Ireland, through an exclusive distribution agreement with a
consumer goods distributor whose deep and established relationships
include nearly every major European retail chain,” commented Jason
Mitchell, N.D., Co-founder and Chief Executive Officer of
HempFusion. “This launch establishes HempFusion’s European presence
and represents the initial phase of the Company’s broader European
expansion plans,” continued Mitchell.
This exclusive European distributor (who will remain unnamed at
this time for competitive purposes) has established significant
relationships providing HempFusion and Probulin access to the
majority of retailers across Ireland, including Natural Retail,
Pharmacy Retail, Food & Drug Mass, Natural and eCommerce
channels. Potential distribution points may include Boots, Lloyds,
Nourish, the Health Store Group, and other natural retailers
representing more than 1,000 stores across Ireland.
The initial distribution of HempFusion and Probulin products
will include the launch of 6 SKUs consisting of four Probulin and
two HempFusion SKUs, with more products expected to launch in the
first half of 2021.
Probulin SKUs launching in Ireland are:
- Women’s Health Probiotic
- Probulin Daily Care Probiotic
- Colon Support
- Total Care Probiotic
HempFusion SKUs launching in Ireland are:
- 10MG USDA Organic Tincture
- 20MG USDA Organic Tincture
ABOUT HEMPFUSION
HempFusion is a leading health and wellness CBD company
utilizing the power of whole-food hemp nutrition. HempFusion
distributes its family of brands, including HempFusion, Probulin
Probiotics, Biome Research, and HF Labs, to approximately 4,000
retailers across all 50 states of the United States and select
international locations. Built on a foundation of regulatory
compliance and human safety, HempFusion’s diverse product portfolio
comprises 46 SKUs including tinctures, proprietary FDA Drug Listed
Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and
more. With a strong focus on research and development, HempFusion
has an additional 30 products under development. HempFusion is a
board member of the US Hemp Roundtable, and HempFusion’s
wholly-owned subsidiary, Probulin Probiotics, is one of the
fastest-growing probiotics companies in the United States,
according to SPINs reported data. HempFusion’s CBD products are
based on a proprietary Whole Food Hemp Complex™ and are available
in-store or by visiting HempFusion online at www.hempfusion.com or
www.probulin.com.
Follow HempFusion on Twitter, Facebook and Instagram and
Probulin on Twitter, Facebook and Instagram.
FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements and
forward-looking information within the meaning of Canadian
securities legislation (collectively, “forward-looking
statements“) that relate to HempFusion’s current expectations
and views of future events. Any statements that express, or involve
discussions as to, expectations, beliefs, plans, objectives,
assumptions or future events or performance (often, but not always,
through the use of words or phrases such as “will likely result”,
“are expected to”, “expects”, “will continue”, “is anticipated”,
“anticipates”, “believes”, “estimated”, “intends”, “plans”,
“forecast”, “projection”, “strategy”, “objective” and “outlook”)
are not historical facts and may be forward-looking statements and
may involve estimates, assumptions and uncertainties which could
cause actual results or outcomes to differ materially from those
expressed in such forward-looking statements. No assurance can be
given that these expectations will prove to be correct and such
forward-looking statements included in this news release should not
be unduly relied upon. These statements speak only as of the date
of this news release. In particular and without limitation, this
news release contains forward-looking statements relating to the
Company’s broader European expansion plans, potential retail
distribution points, the distribution of additional HempFusion and
Probulin products and the Company’s other plans, focus and
objectives.
Forward-looking statements are based on a number of assumptions
and are subject to a number of risks and uncertainties, many of
which are beyond HempFusion’s control, which could cause actual
results and events to differ materially from those that are
disclosed in or implied by such forward-looking statements. Such
risks and uncertainties include, but are not limited to, the impact
and progression of the COVID-19 pandemic and other factors set
forth under “Forward-Looking Statements” and “Risk Factors” in the
final long form prospectus of the Company dated December 17, 2020
and available under the Company’s profile on SEDAR at
www.sedar.com. HempFusion undertakes no obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required
by law. New factors emerge from time to time, and it is not
possible for HempFusion to predict all of them or assess the impact
of each such factor or the extent to which any factor, or
combination of factors, may cause results to differ materially from
those contained in any forward-looking statement. Any
forward-looking statements contained in this news release are
expressly qualified in their entirety by this cautionary
statement.
Neither the TSX nor its Regulation Services Provider (as that
term is defined in the policies of the TSX) accepts responsibility
for the adequacy or accuracy of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210114005361/en/
Jason Mitchell, N.D. Chief Executive Officer and Director Email:
ir@hempfusion.com Phone: 416-803-5638
HempFusion Wellness (TSX:CBD.U)
Historical Stock Chart
From Aug 2024 to Sep 2024
HempFusion Wellness (TSX:CBD.U)
Historical Stock Chart
From Sep 2023 to Sep 2024